RPL17 and non-small cell lung carcinoma: Another study reported that NSCLC patients on anti-PD-1 IO who harbored co-mutations of STK11 and KRAS (n = 36) detected in ctDNA had longer OS in comparison to patients who harbored STK11 mutations alone (13.6 ± 3.4 months, p = 0.049, n = 37) [70].